Vesalius, GSK partner on Parkinson’s disease

GSK has partnered with Vesalius Therapeutics to develop treatments for Parkinson’s disease. Founded by Flagship Pioneering, Vesalius specializes in illuminating the biology causing common diseases and finding new “intervention points.” The start-up says that by creating smaller groups of patients defined by specific biological drivers of their conditions, it can develop customized treatments. Vesalius will receive $80 million up front for its small-molecule Parkinson’s program and has the potential for milestone payments of up to $570 million.